NurExone logo2.png
Updates from NurExone: Growth Conference Presentation and Website Relaunch
July 05, 2024 08:43 ET | NurExone Biologic Inc
TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
Optic Nerve Regeneration - research team
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
June 28, 2024 16:04 ET | NurExone Biologic Inc
Prestigious Eye Institute Exploring New Indication for NurExone’s ExoPTEN
NurExone logo2.png
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development
June 21, 2024 16:04 ET | NurExone Biologic Inc
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company,...
NurExone logo2.png
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
June 11, 2024 08:44 ET | NurExone Biologic Inc
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application
Cytek Logo - Color.jpg
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
May 20, 2024 17:30 ET | Cytek Biosciences, Inc.
Cytek has announced its Enhanced Small Particle Detection Option for its Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
NurExone logo2.png
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine
April 19, 2024 16:04 ET | NurExone Biologic Inc
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at top European Conference on Exosomes and Regenerative Medicine
NurExone logo2.png
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
March 22, 2024 17:04 ET | NurExone Biologic Inc
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN
NurExone logo2.png
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
March 15, 2024 16:05 ET | NurExone Biologic Inc
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence
NurExone logo2.png
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel
March 08, 2024 16:05 ET | NurExone Biologic Inc
NurExone establishing State-of-the-Art Research and Development Facility on Technion Campus in Israel
NurExone logo2.png
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
March 01, 2024 16:04 ET | NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit